Impact of germline BRCA2 and CHEK2 mutations on time to castration resistance in patients with metastatic hormone-naive prostate cancer


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Introduction: as shown in previous studies, mutations in the BRCA1/2 and CHEK2 genes are associated with worsened long-term results of the definitive treatment for localized prostate cancer (PCa). Aim: to evaluate the prognostic value of germline BRCA1/2 and CHEK2 mutations on time to castration-resistance in patients with metastatic PCa (mPCa), receiving hormonal therapy in the first-line systemic treatment. Materials and methods: A total of 76 patients with mPCa receiving hormonal therapy with luteinizing hormone-releasing hormone analogue (LHRHa) in N.N. Blokhin National Medical Research Center of Oncology were recruited in our prospective study. All patients were genotyped for germline mutations in the BRCA1/2 and CHEK2 genes by real-time polymerase chain reaction using a set “OncoGenetics” (LLC “Research and Production Company DNA-Technology”, Russia, registration certificate № 2010/08415) and the Sanger sequencing using a set “Beckman Coulter enomeLab GeXP”. In addition, a histologic grade and volume of metastatic disease were evaluated. Results: Pathogenic and possibly pathogenic mutations in the BRCA2 and CHEK2 gene were identified in 19 (25%) patients. No cases of BRCA1 mutations were detected. Median time to castration resistance was significantly lower in BRCA2 and CHEK2 mutation carriers (7.93 mo, 95% confidence interval (CI) 2.62-13.25), than in non-carriers (48,66 mo, 95% CI 31.05-68.26, p<0,001). Cox analysis confirmed three independent unfavorable prognostic factors. Discussion: The results of our study and other publications have confirmed limited efficacy of standard approach to treatment hormone-sensitive mPCa in germline mutation BRCA2 and CHEK2 carriers. However, the main objective of studies was to assess the survival rates in these patients at the stage of castration-resistant mPCa. Conclusion: Our results demonstrated that germline BRCA2 and CHEK2 mutations are independent unfavorable predictors in patients with mPCa which are associated with decreased time to castration resistance (HR 3.04, 95% CI 1.63-5.66, p<0.001), particularly in subgroup with low volume metastatic disease (HR 4.59, 95% CI 2.06-10.22, p<0,001). An evaluation of a prognostic value of mutations in other DNA repair genes requires additional research.

全文:

受限制的访问

作者简介

V. Matveev

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

A. Kirichek

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Email: akirdoctor@gmail.com

M. Filippova

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

A. Savinkova

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

O. Khalmurzaev

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

L. Lyubchenko

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

参考

  1. Bray F., Ferlay J., Soerjomataram I., et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018:68(6):394-424. doi: 10.3322/caac.21492.
  2. Cornford P., Bellmunt J., Bolla M. et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: Treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017;71(4):630-642. Doi: 10.1016/j. euuro.2016.08.002.
  3. Harris W.P., Mostaghel E.A., Nelson P.S., et al. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol. 2009;6(2):76-85. Doi: 10.1038/ ncpuro1296.
  4. Wu J.N., Fish K.M., Evans C.P. et al. No improvements noted in overall or causespecific survival in patients presented with metastatic prostate cancer over a 20-year period. Cancer 2014;120(6):818-23. Doi: 10.1002/ cncr.28485.
  5. Siegel R.L., Miller K.D., Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67(1):7-30.
  6. Glass T.R., Tangen C.M., Crawford E.D., Thompson I. Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning. J Urol. 2003;169(1):164-169. doi: 10.1097/01.ju.0000042482.18153.30.
  7. Киричек А.А., Камолов Б.Ш., Матвеев В.Б. Обзор материалов конгресса Европейского общества медицинской онкологии (ESMO) 2017 г. Онкоурология. 2017;13(4): 133-140. https://doi.org/10.17650/1726-9776-2017-13-4-133-140
  8. Vale C.L., Burdett S., Rydzewska L.H., et al. Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. Lancet Oncol. 2016;17(2):243-56. doi: 10.1016/S1470-2045(15)00489-1.
  9. Rydzewska, L.H.M., Burdett S., Vale C.L., et al. Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis. Eur J Cancer. 2017;84:88-101. doi: 10.1016/j.ejca.2017.07.003.
  10. Алексеев Б.Я., Андрианов А.Н., Каприн А.Д. Современные подходы к выбору терапии 1-й линии больных метастатическим гормоночувствительным раком предстательной железы. Онкоурология. 2017;13(4):85-90. https://doi.org/10.17650/1726-9776-2017-13-4-85-90
  11. Sweeney C., Chen Y., Liu G., et al. Long term efficacy and QOL data of chemohormonal therapy (C-HT) in low and high volume hormone naive metastatic prostate cancer (PrCa). Ann Oncol 2016;27(6):243-265.
  12. De Bono J.S., Ashworth A. Translating cancer research into targeted therapeutics. Nature. 2010;467(7315):543-9. doi: 10.1038/nature09339.
  13. Castro E., Goh C., Olmos D., et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol. 2013;31(14):1748-1757.
  14. Alanee S.R., Glogowski E.A., Schrader K.A., et al. Clinical features and management of BRCA1 and BRCA2-associated prostate cancer. Front Biosci (Elite Ed). 2014;6:15-30.
  15. Castro E., Goh C., Leongamornlert D., et al. Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localized prostate cancer. Eur Urol. 2015;68(2):186-193.
  16. Матвеев В.Б., Киричек А.А., Савинкова А.В. и др. Влияние герминальных мутаций в гене CHEK2 на выживаемость до биохимического рецидива и безметастатическую выживаемость после радикального лечения у больных раком предстательной железы. Онкоурология. 2018;14(4):53-67. https://doi.org/10.17650/1726-9776-2018-14-4-53-67
  17. Киричек А.А., Камолов Б.Ш., Саве'лов Н.А., Матвеев В.Б. О стадировании онкоурологических заболеваний по обновленной TNM-классификации 8-го издания. Онкоурология. 2018;14(1):166-172. https://doi.org/10.17650/1726-9776-2018-14-1-166-172
  18. Mateo J., Boysen G., Barbieri C.E., et al. DNA repair in prostate cancer: biology and clinical implications. Eur Urol. 2017;71 (3):417-425. doi: 10.1016/j.eururo.2016.08.037
  19. Pritchard C.C., Mateo J., Walsh M.F., et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J Med. 2016;375(5):443-53. doi: 10.1056/NEJMoa1603144.
  20. Annala M., Struss W.J., Warner E.W., et al. Treatment outcomes and tumor loss of heterozygocity in germline DNA repair-deficient prostate cancer. Eur Urol. 2017;72(1):34-42. doi: 10.1016/j.eururo.2017.02.023.
  21. Antonarakis E.S., Lu C., Luber B., et al. Germline DNA-repair gene mutations and outcome in men with metastatic castration-resistant prostate cancer receiving first-line abiraterone and enzalutamide. Eur Urol. 2018;74(2):218-225. doi: 10.1016/j.eururo.2018.01.035.
  22. Antonarakis E.S., Shaukat F., Isaacsson Velho P., et al. Clinical features and therapeutic outcomes in men with advanced prostate cancer and DNA mismatch repair gene mutations. Eur Urol. 2018; S0302-2838(18)30750-4. doi: 10.1016/j.eururo.2018.10.009. PMID: 30337059.
  23. Castro E.M., Romero Laorden N., Piulats Rodriguez J.M., et al. LBA32 PROREPAIR-B: a prospective cohort study of DNA repair defects in metastatic castration resistant prostate cancer (mCRPC). Ann Oncol 2017:28, http://dx.doi.org/10.1093/annonc/ mdx440.025.
  24. Ma Y., He L., Hyang Q., et al. Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report. BMC Med Genet. 2018:19(1):185. doi: 10.1186/s12881-018-0703-9.
  25. Gongora A.B.L., Canedo F.S.N.A., de Melo A.L.A., et al. Tumor lysis syndrome after platinum-based chemotherapy in castration-resistance prostate cancer with a BRCA2 mutation: a case report. Clin Genitourin Cancer. 2019;17(1):e61-e64. doi: 10.1016/j.clgc.2018.09.001.
  26. Purshouse K., Schuh A., Fairfax B.P., et al. Whole-genome sequencing identifies homozygous BRCA2 deletion guiding treatment in dedifferentiated prostate cancer. Cold Spring Harb Mol Case Stud. 2017;3(3):a001362. doi: 10.1101/mcs.a001362.
  27. Ramos J.D., Mostaghel E.A., Pritchard C.C., Yu E.Y. DNA repair pathway in metastatic castration-resistant prostate cancer responders to radium-223. Clin Genitourin Cancer. 2018;16(2):106-110. Doi: 10.1016/j. clgc.2017.11.009.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2019
##common.cookie##